Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267479 | 0.89 | CYP3A4 (0.80) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1882053 | 0.87 | CYP3A4 (0.82) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL12251785 | 0.85 | CYP3A4 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1266480 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1888289 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL2112330 | 0.82 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1266685 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL1878871 | 0.81 | CYP3A4 (0.82) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL12898470 | 0.79 | CYP3A4 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1885724 | 0.79 | CYP3A4 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CYP1A2 4297/4885CYP3A4 3847/4885CYP2C9 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.